ArticleMetabolites2025
Double-Weighted Bayesian Model Combination for Metabolomics Data Description and Prediction.
Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND/
objectivesThis study presents a novel double-weighted Bayesian Ensemble Machine Learning (DW-EML) model aimed at improving the classification and prediction of metabolomics data. This discipline, which involves the comprehensive analysis of metabolites in a biological system, provides valuable insights into complex biological processes and disease states. As metabolomics assumes an increasingly prominent role in the diagnosis of human diseases and in precision medicine, there is a pressing need for more robust artificial intelligence tools that can offer enhanced reliability and accuracy in medical applications. The proposed DW-EML model addresses this by integrating multiple classifiers within a double-weighted voting scheme, which assigns weights based on the cross-validation accuracy and classification confidence, ensuring a more reliable prediction framework.
methodsThe model was applied to publicly available datasets derived from studies on critical illness in children, chronic typhoid carriage, and early detection of ovarian cancer.
resultsThe results demonstrate that the DW-EML approach outperformed methods traditionally used in metabolomics, such as the Partial Least Squares Discriminant Analysis in terms of accuracy and predictive power.
conclusionsThe DW-EML model is a promising tool for metabolomic data analysis, offering enhanced robustness and reliability for diagnostic and prognostic applications and potentially contributing to the advancement of personalized and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.